Description

Proline + Dapagliflozin Tablets (brand name: Huiyoujing, ) are a newly approved dual-component antidiabetic treatment. By combining proline with dapagliflozin (an SGLT 2 inhibitor), this formulation enables dual pathways in non insulin-dependent glucose control.

Dapagliflozin has been shown to reduce blood-glucose levels by inhibiting glucose reabsorption in the renal tubules and has demonstrated weight reduction, cardiovascular, and renal protective benefits, with a favorable safety profile reddit.com+3finance.sina.com.cn+3reddit.com+3. Approved in China as a national first-class innovative drug, Huiyoujing marks the second domestically developed SGLT 2 agent to reach the market.

Product Specifications

Mechanism of Action

• Proline: May modulate glucose metabolism and serve as an adjunct for stress response regulation.

• Dapagliflozin: A selective SGLT 2 inhibitor that lowers blood glucose by promoting renal glucose excretion. Recognized for additional weight reduction, blood pressure management, and renal and cardiovascular benefits.

Combining these two agents provides a multifaceted research platform to investigate glucose homeostasis, metabolic pathways, and the holistic effects of dual-component therapies.

Why Choose This Product?

• Innovative Dual-Component Formula: Unique combination of Proline and Dapagliflozin.

• First-in-Class, NMPA-Approved: Recognized as a Class?1 innovative drug in China.

• Strong Backing: Developed by Beijing Sihuan Pharmaceutical—a trusted GMP manufacturer.

• Research-Ready Packaging: Sealed blister format, ideal for lab stability and tracking.